Patents by Inventor Camellia Adams

Camellia Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DR5 antibodies and uses thereof
    Publication number: 20070031414
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Application
    Filed: October 10, 2006
    Publication date: February 8, 2007
    Inventor: Camellia Adams
  • DR5 antibodies and uses thereof
    Publication number: 20060269554
    Abstract: The invention concerns anti-DR5 antibodies with improved properties, compositions comprising such antibodies, methods and means for making such antibodies, and their therapeutic use, in particular in the treatment of cancer.
    Type: Application
    Filed: January 30, 2006
    Publication date: November 30, 2006
    Inventor: Camellia Adams
  • Apo-2 receptor
    Publication number: 20060251647
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: November 9, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • Antibody variants and uses thereof
    Publication number: 20060246004
    Abstract: The invention provides improved humanized CD20 binding antibodies for treatment of B cell malignancies and autoimmune diseases.
    Type: Application
    Filed: February 6, 2006
    Publication date: November 2, 2006
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Henry Lowman, Gerald Nakamura
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Publication number: 20060216285
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Application
    Filed: May 5, 2006
    Publication date: September 28, 2006
    Inventors: Camellia Adams, Leonard Presta, Mark Sliwkowski
  • Treatment with anti-ErbB2 antibodies and chemotherapeutic agents
    Publication number: 20060198843
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.
    Type: Application
    Filed: May 5, 2006
    Publication date: September 7, 2006
    Inventors: Camellia Adams, Leonard Presta, Mark Sliwkowski
  • Human anti-factor IX/IXa antibodies
    Publication number: 20060193851
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: March 31, 2006
    Publication date: August 31, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett
  • Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
    Publication number: 20060193854
    Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
    Type: Application
    Filed: May 5, 2006
    Publication date: August 31, 2006
    Inventors: Camellia Adams, Leonard Presta, Mark Sliwkowski
  • Agonist antibodies
    Publication number: 20060177441
    Abstract: Various forms of c-mpl agonist antibodies are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Application
    Filed: April 12, 2006
    Publication date: August 10, 2006
    Inventors: Camellia Adams, Austin Gurney
  • Apo-2 receptor
    Publication number: 20060115484
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: June 1, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • HUMAN ANTI-FACTOR IX/IXA ANTIBODIES
    Publication number: 20060088534
    Abstract: The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
    Type: Application
    Filed: July 8, 2003
    Publication date: April 27, 2006
    Inventors: Camellia Adams, Brigitte Devaux, Dan Eaton, Philip Hass, J. Judice, Daniel Kirchhofer, Shelley Suggett
  • Apo-2 receptor
    Publication number: 20060084147
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: April 20, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • Apo-2 receptor
    Publication number: 20060073570
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: December 9, 2005
    Publication date: April 6, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
    Publication number: 20060073143
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.
    Type: Application
    Filed: September 9, 2005
    Publication date: April 6, 2006
    Inventors: Camellia Adams, Leonard Presta, Mark Sliwkowski
  • Polypeptide variants with altered effector function
    Publication number: 20060067930
    Abstract: The invention provides polypeptides having IgG Fc regions with amino acid modifications that result in the polypeptides exhibiting altered Fc effector functions.
    Type: Application
    Filed: August 19, 2005
    Publication date: March 30, 2006
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Samantha Lien, Henry Lowman, Jonathan Marvin, Yu-Ju Meng
  • Apo-2 receptor
    Publication number: 20060035334
    Abstract: Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.
    Type: Application
    Filed: October 7, 2005
    Publication date: February 16, 2006
    Inventors: Camellia Adams, Avi Ashkenazi, Anan Chuntharapai, Kyung Kim
  • Immunoglobulin variants and uses thereof
    Publication number: 20060034835
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: June 7, 2005
    Publication date: February 16, 2006
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Andrew Chan, Craig Crowley, Henry Lowman, Gerald Nakamura, Leonard Presta
  • Treatment with anti-ErbB2 antibody combinations
    Publication number: 20060034842
    Abstract: The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.
    Type: Application
    Filed: September 9, 2005
    Publication date: February 16, 2006
    Inventors: Camellia Adams, Leonard Presta, Mark Sliwkowski
  • Immunoglobulin variants and uses thereof
    Publication number: 20060024300
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: July 26, 2005
    Publication date: February 2, 2006
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Andrew Chan, Craig Crowley, Henry Lowman, Gerald Nakamura, Leonard Presta
  • Humanized anti-TGF-beta antibodies
    Publication number: 20050276802
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Application
    Filed: March 31, 2005
    Publication date: December 15, 2005
    Applicant: Genentech, Inc.
    Inventors: Camellia Adams, Napoleone Ferrara, Ellen Filvaroff, Weiguang Mao, Leonard Presta, Max Tejada